Hiroshi Sasaki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1406033/publications.pdf

Version: 2024-02-01

933447 642732 40 578 10 23 citations h-index g-index papers 47 47 47 560 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: A morphometric study. Journal of Pathology, 1992, 168, 257-262.	4.5	248
2	Prostaglandin J2 and Related Compounds Annals of the New York Academy of Sciences, 1994, 744, 161-165.	3.8	34
3	Transperineal prostate brachytherapy, using I-125 seed with or without adjuvant androgen deprivation, in patients with intermediate-risk prostate cancer: study protocol for a phase III, multicenter, randomized, controlled trial. BMC Cancer, 2010, 10, 572.	2.6	34
4	Lactate dehydrogenase predicts combined progressionâ€free survival after sequential therapy with abiraterone and enzalutamide for patients with castrationâ€resistant prostate cancer. Prostate, 2017, 77, 1144-1150.	2.3	29
5	Salvage partial brachytherapy for prostate cancer recurrence after primary brachytherapy. International Journal of Urology, 2014, 21, 572-577.	1.0	24
6	Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS): first analysis on survival. International Journal of Clinical Oncology, 2018, 23, 1148-1159.	2.2	21
7	Lateral view dissection of the prostatoâ€urethral junction to reduce positive apical margin in laparoscopic radical prostatectomy. International Journal of Urology, 2009, 16, 664-669.	1.0	17
8	Safety of fondaparinux for prevention of postoperative venous thromboembolism in urological malignancy: A prospective randomized clinical trial. International Journal of Urology, 2016, 23, 923-928.	1.0	17
9	Upfront transection and subsequent ligation of the dorsal vein complex during laparoscopic radical prostatectomy. International Journal of Urology, 2010, 17, 960-961.	1.0	15
10	Prognostic Significance of Prostate-Specific Antigen Persistence after Radical Prostatectomy: A Systematic Review and Meta-Analysis. Cancers, 2021, 13, 948.	3.7	13
11	The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN study. International Journal of Clinical Oncology, 2020, 25, 2107-2114.	2.2	10
12	Earlier use of androgen receptorâ€exisâ€targeted drugs may improve overall survival in patients with nonâ€metastatic castrationâ€resistant prostate cancer. Prostate, 2018, 78, 766-772.	2.3	9
13	Shortâ€ŧerm impact of androgen deprivation therapy on bone strength in castrationâ€sensitive prostate cancer. International Journal of Urology, 2019, 26, 980-984.	1.0	9
14	Health-related quality of life in Japanese low-risk prostate cancer patients choosing active surveillance: 3-year follow-up from PRIAS-JAPAN. World Journal of Urology, 2021, 39, 2491-2497.	2.2	9
15	Midâ€term outcome of permanent prostate iodineâ€125 brachytherapy in <scp>J</scp> apanese patients. International Journal of Urology, 2014, 21, 473-478.	1.0	8
16	Gonadotropin-releasing hormone antagonist: A real advantage?. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 322-328.	1.6	7
17	How long is long enough to secure disease control after low-dose-rate brachytherapy in combination with other modalities in intermediate-risk, localized prostate cancer?. International Journal of Clinical Oncology, 2022, 27, 184-193.	2.2	7
18	A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer. BMC Cancer, 2016, 16, 708.	2.6	6

#	Article	IF	CITATIONS
19	Prospective comparison of the efficacy of caudal versus periprostatic nerve block, both with intrarectal local anesthesia, during transrectal ultrasonography-guided prostatic needle biopsy. Scandinavian Journal of Urology, 2017, 51, 245-250.	1.0	6
20	Prognostic value of PSA bounce in prostate cancer following definitive radiation therapy: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases, 2021, 24, 976-985.	3.9	6
21	Do androgen deprivation and the biologically equivalent dose matter in lowâ€doseâ€rate brachytherapy for intermediateâ€risk prostate cancer?. Cancer Medicine, 2016, 5, 2314-2322.	2.8	5
22	In Vivo Development of Fetal Pig Kidneys in Mature Monkeys under Clinically Approved Immunosuppressant Drugs. Engineering, 2022, 10, 65-73.	6.7	5
23	Outcomes of laparoscopic resection of urachal remnants followed by novel umbilicoplasty. International Urology and Nephrology, 2018, 50, 2167-2172.	1.4	4
24	Techniques of orthotopic renal transplantation. II. Size-matched porcine grafts in monkey recipients. Acta Cirurgica Brasileira, 2021, 36, e360503.	0.7	4
25	The Impact of ABO Blood Type on Developing Venous Thromboembolism in Cancer Patients: Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 3692.	2.4	4
26	Deferred radical prostatectomy in patients who initially elected for active surveillance: a multi-institutional, prospective, observational cohort of the PRIAS-JAPAN study. International Journal of Clinical Oncology, 2022, 27, 194-201.	2.2	4
27	Clinical significance of unfavorable findings in intermediateâ€risk prostate cancer patients for predicting treatment outcomes after contemporary, doseâ€escalated multimodal radiotherapy. Prostate, 2022, 82, 433-441.	2.3	4
28	Pulmonary Metastases After Low-Dose-Rate Brachytherapy for Localized Prostate Cancer. Korean Journal of Urology, 2014, 55, 309.	1.2	3
29	Impact of adherence to criteria on oncological outcomes of radical prostatectomy in patients opting for active surveillance: data from the PRIAS-JAPAN study. Japanese Journal of Clinical Oncology, 0, , .	1.3	3
30	Results of central pathology review of prostatic biopsies in a contemporary series from a phase <scp>III</scp> , multicenter, randomized controlled trial (<scp>SHIP0804</scp>). Pathology International, 2015, 65, 177-182.	1.3	2
31	Impact of health-related quality of life on repeat protocol biopsy compliance on active surveillance for favorable prostate cancer: results from a prospective cohort in the PRIAS-JAPAN study. Urologic Oncology: Seminars and Original Investigations, 2021, 40, 56.e9-56.e9.	1.6	2
32	Differences in sex hormone recovery profile after cessation of 12â€week gonadotropinâ€releasing hormone antagonist versus agonist therapy. Andrology, 2021, , .	3.5	2
33	No survival benefit found after extended treatment with docetaxel for patients with castration $\hat{a} \in \mathbf{r}$ esistant prostate cancer. Prostate, 2019, 79, 1604-1610.	2.3	1
34	Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer. International Journal of Clinical Oncology, 2020, 25, 479-485.	2.2	1
35	Novel technique to secure closure of the umbilical defect and umbilical reconstruction after laparoscopic resection of urachal remnant. International Journal of Urology, 2020, 27, 1158-1160.	1.0	0
36	High-dose-rate (HDR) brachytherapy with external beam radiotherapy for localized high-risk prostate cancer: Five-year results in 122 patients Journal of Clinical Oncology, 2012, 30, 91-91.	1.6	0

#	Article	IF	CITATIONS
37	Systemic chemotherapy compared with radiation therapy as adjuvant therapy after radical surgery in high-risk stage IB-IIB cervical adenocarcinoma Journal of Clinical Oncology, 2014, 32, 5598-5598.	1.6	0
38	Outcomes of the patients with pTO on first protocol biopsy during active surveillance for early prostate cancer: From the PRIAS-JAPAN study Journal of Clinical Oncology, 2019, 37, 20-20.	1.6	0
39	Comparison of the medical costs between active surveillance and other treatment for early prostate cancer in Japan: From the data of PRIAS JAPAN study Journal of Clinical Oncology, 2022, 40, 280-280.	1.6	O
40	Pathological and oncological outcomes of off-criteria radical prostatectomy in patients opting for active surveillance: From PRIAS-JAPAN Journal of Clinical Oncology, 2022, 40, 250-250.	1.6	0